Abstract
Proprotein subtilisin kexin type 9 (PCSK9) and lipoprotein (a) [Lp(a)] levels are causative risk factors for coronary heart disease. The objective of the study was to determine the impact of lipid-lowering treatments on circulating PCSK9 and Lp(a). We measured PCSK9 and Lp(a) levels in plasma samples from Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial patients with coronary heart disease and/or type II diabetes (T2D) mellitus. Patients received atorvastatin, which was titrated (10, 20, 40, or 80mg/d) to achieve low-density lipoprotein cholesterol levels <100mg/dL (baseline) and were subsequently randomized either to atorvastatin+torcetrapib, a cholesterol ester transfer protein inhibitor, or to atorvastatin+placebo. At baseline, both plasma PCSK9 and Lp(a) were dose-dependently increased with increasing atorvastatin doses. Compared with patients without T2D, those with T2D had higher PCSK9 (357±123 vs 338±115ng/mL, P=.0012) and lower Lp(a) levels (28±32 vs 32±33mg/dL, P=.0005). Plasma PCSK9 levels significantly increased in patients treated with torcetrapib (+13.1±125.3ng/mL [+3.7%], P=.005), but not in patients treated with placebo (+2.6±127.9ng/mL [+0.7%], P=.39). Plasma Lp(a) levels significantly decreased in patients treated with torcetrapib (-3.4±10.7mg/dL [-11.1%], P<.0001), but not in patients treated with placebo (+0.3±9.4mg/dL [+0.1%], P=.92). In patients at high cardiovascular disease risk, PCSK9 and Lp(a) are positively and dose-dependently correlated with atorvastatin dosage, whereas the presence of T2D is associated with higher PCSK9 but lower Lp(a) levels. Cholesterol ester transfer protein inhibition with torcetrapib slightly increases PCSK9 levels and decreases Lp(a) levels.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.